Hospice of St. Christopher in Warsaw, Warsaw, Poland.
Medical University of Warsaw, Warsaw, Poland.
Drug Alcohol Depend. 2021 Apr 1;221:108652. doi: 10.1016/j.drugalcdep.2021.108652. Epub 2021 Feb 26.
Since the introduction of the National Medical Cannabis Programme in The Netherlands, many other countries in Europe have made medical cannabis (MC) and cannabis-based medicines (CBMs) available. However, each of them has implemented a unique legal framework and reimbursement strategy for these products. Therefore, it is vital to study healthcare professionals' knowledge level (HCP) and HCPs in-training regarding both medical uses and indications and understand their safety concerns and potential barriers for MC use in clinical practice.
A comprehensive, systematic literature review was performed using PubMed/MEDLINE, EMBASE, and Google Scholar databases, as well as PsychINFO. Grey literature was also included. Due to the high diversity in the questionnaires used in the studies, a narrative synthesis was performed.
From 6995 studies retrieved, ten studies, all of them being quantitative survey-based studies, were included in the review. In most studies, the majority of participants were in favor of MC and CBMs use for medical reasons. Other common findings were: the necessity to provide additional training regarding medical applications of cannabinoids, lack of awareness about the legal status of and regulations regarding MC among both certified physicians, as well as prospective doctors and students of other medicals sciences (e.g., nursing, pharmacy).
For most European countries, we could not identify any studies evaluating HCPs' knowledge and attitudes towards medicinal cannabis. Therefore, similar investigations are highly encouraged. Available evidence demonstrates a need to provide medical training to the HCPs in Europe regarding medical applications of cannabinoids.
自荷兰推出国家医用大麻计划以来，欧洲许多其他国家也开始提供医用大麻（MC）和大麻素类药物（CBM）。然而，每个国家都为这些产品实施了独特的法律框架和报销策略。因此，研究医疗保健专业人员（HCP）对医用大麻的医疗用途和适应证的了解程度以及他们对 MC 使用的安全顾虑和潜在障碍，以及对医学生的培训至关重要。
使用 PubMed/MEDLINE、EMBASE 和 Google Scholar 数据库以及 PsychINFO 进行全面的系统文献回顾，并纳入灰色文献。由于研究中使用的问卷存在高度多样性，因此进行了叙述性综合。
从 6995 项研究中检索到的研究中，有十项研究被纳入了综述，这些研究均为基于定量调查的研究。在大多数研究中，大多数参与者赞成出于医疗原因使用 MC 和 CBM。其他常见的发现包括：需要提供有关大麻素医学应用的额外培训，合格医生以及其他医学科学（如护理、药学）的准医生和学生对 MC 的法律地位和法规缺乏认识。
对于大多数欧洲国家，我们无法确定有任何研究评估 HCP 对医用大麻的知识和态度。因此，强烈鼓励进行类似的调查。现有证据表明，欧洲需要为 HCP 提供有关大麻素医学应用的医学培训。
